SCHEMBL13868699

SCHEMBL13868699

COc1ccc(-c2cc3c4c(cc(O)c3cc2C2CCCCC2)C2(c3ccccc3-c3ccccc32)c2ccccc2-4)cc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CAMKK2 Q96RR4 2/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
CHUK O15111 1/20 0.35
INSR P06213 1/20 0.35
MAPK8 P45983 1/20 0.35
PDK2 Q15119 1/20 0.35
MAPK1 P28482 2/20 0.34
POLB P06746 1/20 0.34
ALOX15 P16050 1/20 0.34
ALOX12 P18054 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12424633 0.79 ESR1 (0.40) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL26629585 0.76 CNR2 (0.35) MEN1KMT2ACAMKK2HPGDHSD17B10
SCHEMBL10261758 0.71 PTGDR2 (0.33) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL12424610 0.71 EHMT2 (0.35) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL12424649 0.70 KMT2A (0.33) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL24799508 0.69 EHMT2 (0.36) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL12424645 0.69 PARP1 (0.35) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL8513816 0.68 PDK2 (0.47) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL30125488 0.68 PDK2 (0.47) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL165110 0.67 PDK2 (0.40) RAB9AMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070215844-A1 Chromene Compound CRY2, TYR, CRY1 NPC1 2865/4885RAB9A 2789/4885MEN1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.